Cyr61/CTGF/Nov family proteins in gastric carcinogenesis

World Journal of Gastroenterology

Volumn 20, Issue 7, 2014, Pages 1694-1700

  Cheng, Tsu Yao ^a   Wu, Ming Shiang ^a   Hua, Kuo Tai ^b   Kuo, Min Liang ^b   Lin, Ming Tsan ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Connective tissue growth factor; Cyr61 CTGF Nov proteins; Cysteine rich angiogenic inducer 61; Gastric cancer; Gastric carcinogenesis; Nephroblastoma over expressed

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOOXYGENASE 2; CYSTEINE RICH PROTEIN 61; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; SOMATOMEDIN BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; WNT1 PROTEIN; CCN PROTEIN; CTGF PROTEIN, HUMAN; NOV PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CARCINOGENESIS; HUMAN; METASTASIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; SURVIVAL RATE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; CHEMISTRY; GENE EXPRESSION REGULATION; METABOLISM; MORTALITY; PROTEIN TERTIARY STRUCTURE; RNA INTERFERENCE; STOMACH TUMOR;

ANTIBODIES, MONOCLONAL; CARCINOGENESIS; CCN INTERCELLULAR SIGNALING PROTEINS; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE-RICH PROTEIN 61; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM METASTASIS; NEPHROBLASTOMA OVEREXPRESSED PROTEIN; PROTEIN SORTING SIGNALS; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84894229065     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i7.1694     Document Type: Article

References (70)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
3. Chong HC, Tan CK, Huang RL, Tan NS. Matricellular proteins: a sticky affair with cancers. J Oncol 2012; 2012: 351089 [PMID: 22481923 DOI: 10.1155/2012/351089]
4. Perbal B. CCN proteins: A centralized communication network. J Cell Commun Signal 2013; 7: 169-177 [PMID: 23420091 DOI: 10.1007/s12079-013-0193-7]
5. Chen CC, Lau LF. Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol 2009; 41: 771-783 [PMID: 18775791 DOI: 10.1016/j.biocel.2008.07.025]
6. Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011; 10: 945-963 [PMID: 22129992 DOI: 10.1038/ nrd3599]
7. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett 1993; 327: 125-130 [PMID: 7687569]
8. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, Maehara Y, Sugimachi K. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 2001; 20: 5525-5532 [PMID: 11571650 DOI: 10.1038/sj.onc.1204723]
9. Thorstensen L, Diep CB, Meling GI, Aagesen TH, Ahrens CH, Rognum TO, Lothe RA. WNT1 inducible signaling pathway protein 3, WISP-3, a novel target gene in colorectal carcinomas with microsatellite instability. Gastroenterology 2001; 121: 1275-1280 [PMID: 11729105 DOI: 10.1053/ gast.2001.29570]
10. Tanaka S, Sugimachi K, Shimada M, Maehara Y, Sugimachi K. Variant WISPs as targets for gastrointestinal carcinomas. Gastroenterology 2002; 123: 392-393 [PMID: 12105881 DOI: 10.1053/gast.2002.34589]
11. Li Z, Li J. Local expressions of TGF-beta1, TGF-beta1RI, CTGF, and Smad-7 in Helicobacter pylori-associated gastritis. Scand J Gastroenterol 2006; 41: 1007-1012 [PMID: 16938712 DOI: 10.1080/00365520600554477]
12. Lau LF, Nathans D. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J 1985; 4: 3145-3151 [PMID: 3841511]
13. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687 [PMID: 12297042 DOI: 10.1016/S0092-8674(02)00971-6]
14. Lau LF. CCN1/CYR61: the very model of a modern matricellular protein. Cell Mol Life Sci 2011; 68: 3149-3163 [PMID: 21805345. DOI: 10.1007/s00018-011-0778-3]
15. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61: 8917-8923 [PMID: 11751417]
16. Tsai MS, Hornby AE, Lakins J, Lupu R. Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000; 60: 5603-5607 [PMID: 11059746]
17. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10: 2072-2081 [PMID: 15041728]
18. Zeng ZJ, Yang LY, Ding X, Wang W. Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance. World J Gastroenterol 2004; 10: 3414-3418 [PMID: 15526358]
19. D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH. Extracellular matrix associated protein CYR61 is linked to prostate cancer development. J Urol 2010; 183: 1604-1610 [PMID: 20172544 DOI: 10.1016/ j.juro.2009.12.006]
20. Kok SH, Chang HH, Tsai JY, Hung HC, Lin CY, Chiang CP, Liu CM, Kuo MY. Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: An independent marker for poor prognosis. Head Neck 2010; 32: 1665-1673 [PMID: 20848406. DOI: 10.1002/hed.21381]
21. Sampath D, Zhu Y, Winneker RC, Zhang Z. Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/ Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas. J Clin Endocrinol Metab 2001; 86: 1707-1715 [PMID: 11297607. DOI: 10.1210/jc.86.4.1707]
22. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, Shi XL, Koeffler HP, Tong XJ, Xie D. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2007; 2: e534 [PMID: 17579708 DOI: 10.1371/journal. pone.0000534]
23. Kireeva ML, Lam SC, Lau LF. Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin alphavbeta3. J Biol Chem 1998; 273: 3090-3096 [PMID: 9446626 DOI: 10.1074/ jbc.273.5.3090]
24. Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH, Chen WJ, Kuo ML. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res 2005; 11: 5809-5820 [PMID: 16115920]
25. Chen CC, Mo FE, Lau LF. The angiogenic factor Cyr61 activates a genetic program for wound healing in human skin fibroblasts. J Biol Chem 2001; 276: 47329-47337 [PMID: 11584015. DOI: 10.1074/jbc.M107666200]
26. Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF. CYR61 (CCN1) is essential for placental development and vascular integrity. Mol Cell Biol 2002; 22: 8709-8720 [PMID: 12446788 DOI: 10.1128/MCB.22.24.8709-8720.2002]
27. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998; 95: 6355-6360 [PMID: 9600969]
28. Ohno R, Yoshinaga K, Fujita T, Hasegawa K, Iseki H, Tsunozaki H, Ichikawa W, Nihei Z, Sugihara K. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer 2001; 91: 1876-1881 [PMID: 11346869. DOI: 10.1002/1097-0142(20010515)91]
29. Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H, Hori M. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 451-455 [PMID: 10022645. DOI: 10.1111/j.1572-0241.1999.876_e.x]
30. Yu HG, Li JY, Yang YN, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Increased abundance of cyclooxygenase-2 correlates with vascular endothelial growth factor-A abundance and tumor angiogenesis in gastric cancer. Cancer Lett 2003; 195: 43-51 [PMID: 12767510]
31. Lin MT, Kuo IH, Chang CC, Chu CY, Chen HY, Lin BR, Sureshbabu M, Shih HJ, Kuo ML. Involvement of hypoxiainducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion. J Biol Chem 2008; 283: 15807-15815 [PMID: 18381294. DOI: 10.1074/jbc.M708933200]
32. Lin MT, Chang CC, Lin BR, Yang HY, Chu CY, Wu MH, Kuo ML. Elevated expression of Cyr61 enhances peritoneal dissemination of gastric cancer cells through integrin alpha-2beta1. J Biol Chem 2007; 282: 34594-34604 [PMID: 17905740 DOI: 10.1074/jbc.M706600200]
33. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRCinduced immediate early gene product CEF-10. J Cell Biol 1991; 114: 1285-1294 [PMID: 1654338]
34. Koliopanos A, Friess H, di Mola FF, Tang WH, Kubulus D, Brigstock D, Zimmermann A, Büchler MW. Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002; 26: 420-427 [PMID: 11910473. DOI: 10.1007/s00268-001-0242-x]
35. Hartel M, Di Mola FF, Gardini A, Zimmermann A, Di Sebastiano P, Guweidhi A, Innocenti P, Giese T, Giese N, Büchler MW, Friess H. Desmoplastic reaction influences pancreatic cancer growth behavior. World J Surg 2004; 28: 818-825 [PMID: 15457365]
36. Braig S, Wallner S, Junglas B, Fuchshofer R, Bosserhoff AK. CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration. Br J Cancer 2011; 105: 231-238 [PMID: 21673687 DOI: 10.1038/bjc.2011.226]
37. Chang CC, Shih JY, Jeng YM, Su JL, Lin BZ, Chen ST, Chau YP, Yang PC, Kuo ML. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004; 96: 364-375 [PMID: 14996858 DOI: 10.1093/jnci/djh059]
38. Lin BR, Chang CC, Che TF, Chen ST, Chen RJ, Yang CY, Jeng YM, Liang JT, Lee PH, Chang KJ, Chau YP, Kuo ML. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology 2005; 128: 9-23 [PMID: 15633118 DOI: 10.1053/j.gastro.2004.10.007]
39. Liu L, Li Z, Feng G, You W, Li J. Expression of connective tissue growth factor is in agreement with the expression of VEGF, VEGF-C,-D and associated with shorter survival in gastric cancer. Pathol Int 2007; 57: 712-718 [PMID: 17922682 DOI: 10.1111/j.1440-1827.2007.02162.x]
40. Liu LY, Han YC, Wu SH, Lv ZH. Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer. World J Gastroenterol 2008; 14: 2110-2114 [PMID: 18395916]
41. Jiang CG, Lv L, Liu FR, Wang ZN, Liu FN, Li YS, Wang CY, Zhang HY, Sun Z, Xu HM. Downregulation of connective tissue growth factor inhibits the growth and invasion of gastric cancer cells and attenuates peritoneal dissemination. Mol Cancer 2011; 10: 122 [PMID: 21955589 DOI: 10.1186/1476-459 8-10-122]
42. Walker JL, Assoian RK. Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression. Cancer Metastasis Rev 2005; 24: 383-393 [PMID: 16258726. DOI: 10.1007/s10555-005-5130-7]
43. Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K, Ikeda E, Takata S, Kobayashi K, Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J 2002; 16: 219-221 [PMID: 11744618 DOI: 10.1096/fj.01-0332fje]
44. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol 2004; 287: F1223-F1232 [PMID: 15315937. DOI: 10.1152/ajprenal.00245.2004]
45. Joliot V, Martinerie C, Dambrine G, Plassiart G, Brisac M, Crochet J, Perbal B. Proviral rearrangements and overexpression of a new cellular gene (nov) in myeloblastosis-associated virus type 1-induced nephroblastomas. Mol Cell Biol 1992; 12: 10-21 [PMID: 1309586]
46. Ouellet V, Siegel PM. CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis. J Cell Commun Signal 2012; 6: 73-85 [PMID: 22427255 DOI: 10.1007/ s12079-012-0161-7]
47. Martinerie C, Huff V, Joubert I, Badzioch M, Saunders G, Strong L, Perbal B. Structural analysis of the human nov proto-oncogene and expression in Wilms tumor. Oncogene 1994; 9: 2729-2732 [PMID: 7520150]
48. Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, Yeger H, Picci P, Scotlandi K. The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol 2002; 160: 849-859 [PMID: 11891184 DOI: 10.1016/S0002-9440(10)64908-5]
49. Martinerie C, Gicquel C, Louvel A, Laurent M, Schofield PN, Le Bouc Y. Altered expression of novH is associated with human adrenocortical tumorigenesis. J Clin Endocrinol Metab 2001; 86: 3929-3940 [PMID: 11502835 DOI: 10.1210/ jc.86.8.3929]
50. Wu L, Runkle C, Jin HJ, Yu J, Li J, Yang X, Kuzel T, Lee C, Yu J. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor. Oncogene 2013. Jan 14; Epub ahead of print [PMID: 23318417 DOI: 10.1038/onc.2012.602]
51. Hashimoto Y, Shindo-Okada N, Tani M, Takeuchi K, Toma H, Yokota J. Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res 1996; 56: 5266-5271 [PMID: 8912867]
52. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1-and beta-catenin-responsive oncogene. Genes Dev 2000; 14: 585-595 [PMID: 10716946 DOI: 10.1101/ gad.14.5.585]
53. Hashimoto Y, Shindo-Okada N, Tani M, Nagamachi Y, Takeuchi K, Shiroishi T, Toma H, Yokota J. Expression of the Elm1 gene, a novel gene of the CCN (connective tissue growth factor, Cyr61/Cef10, and neuroblastoma overexpressed gene) family, suppresses In vivo tumor growth and metastasis of K-1735 murine melanoma cells. J Exp Med 1998; 187: 289-296 [PMID: 9449709]
54. Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, Brush J, Taneyhill LA, Deuel B, Lew M, Watanabe C, Cohen RL, Melhem MF, Finley GG, Quirke P, Goddard AD, Hillan KJ, Gurney AL, Botstein D, Levine AJ. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA 1998; 95: 14717-14722 [PMID: 9843955]
55. Tian C, Zhou ZG, Meng WJ, Sun XF, Yu YY, Li L, Luo HZ, Yang L, Zhou B, Gu J. Overexpression of connective tissue growth factor WISP-1 in Chinese primary rectal cancer patients. World J Gastroenterol 2007; 13: 3878-3882 [PMID: 17657846]
56. Davies SR, Davies ML, Sanders A, Parr C, Torkington J, Jiang WG. Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. Int J Oncol 2010; 36: 1129-1136 [PMID: 20372786 DOI: 10.3892/ijo_00000595]
57. Nagai Y, Watanabe M, Ishikawa S, Karashima R, Kurashige J, Iwagami S, Iwatsuki M, Baba Y, Imamura Y, Hayashi N, Baba H. Clinical significance of Wnt-induced secreted protein-1 (WISP-1/CCN4) in esophageal squamous cell carcinoma. Anticancer Res 2011; 31: 991-997 [PMID: 21498727]
58. Tang Q, Jiang X, Li H, Lin Z, Zhou X, Luo X, Liu L, Chen G. Expression and prognostic value of WISP-1 in patients with endometrial endometrioid adenocarcinoma. J Obstet Gynaecol Res 2011; 37: 606-612 [PMID: 21564416 DOI: 10.1111/ j.1447-0756.2011.01631.x]
59. Ono M, Inkson CA, Sonn R, Kilts TM, de Castro LF, Maeda A, Fisher LW, Robey PG, Berendsen AD, Li L, McCartney-Francis N, Brown AC, Crawford NP, Molinolo A, Jain A, Fedarko NS, Young MF. WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone. PLoS One 2013; 8: e71709 [PMID: 23977121 DOI: 10.1371/journal. pone.0071709]
60. Zhang R, Averboukh L, Zhu W, Zhang H, Jo H, Dempsey PJ, Coffey RJ, Pardee AB, Liang P. Identification of rCop-1, a new member of the CCN protein family, as a negative regulator for cell transformation. Mol Cell Biol 1998; 18: 6131-6141 [PMID: 9742130]
61. Dhar G, Mehta S, Banerjee S, Gardner A, McCarty BM, Mathur SC, Campbell DR, Kambhampati S, Banerjee SK. Loss of WISP-2/CCN5 signaling in human pancreatic cancer: a potential mechanism for epithelial-mesenchymaltransition. Cancer Lett 2007; 254: 63-70 [PMID: 17383817]
62. Banerjee S, Dhar G, Haque I, Kambhampati S, Mehta S, Sengupta K, Tawfik O, Phillips TA, Banerjee SK. CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 2008; 68: 7606-7612 [PMID: 18794149 DOI: 10.1158/0008-5472.CAN-08-1461]
63. Kleer CG, Zhang Y, Pan Q, van Golen KL, Wu ZF, Livant D, Merajver SD. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002; 21: 3172-3180 [PMID: 12082632 DOI: 10.1038/sj.onc.1205462]
64. Huang W, Zhang Y, Varambally S, Chinnaiyan AM, Banerjee M, Merajver SD, Kleer CG. Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol 2008; 172: 893-904 [PMID: 18321996 DOI: 10.2353/ajpath. 2008.070899]
65. van Golen KL, Davies S, Wu ZF, Wang Y, Bucana CD, Root H, Chandrasekharappa S, Strawderman M, Ethier SP, Merajver SD. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5: 2511-2519 [PMID: 10499627]
66. Tanaka S, Sugimachi K, Maehara S, Shimada M, Maehara Y. A loss of function mutation in WISP3 derived from microsatellite unstable gastric carcinoma. Gastroenterology 2003; 125: 1563-1564 [PMID: 14628823 DOI: 10.1053/ S0016-5085(03)01467-7]
67. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]
68. Mageto Y, Flaherty K, Brown K, Fong A, Raghu G. Safety and tolerability of human monoclonal antibody FG-3019, anti-connective tissue growth factor, in patients with idiopathic pulmonary fibrosis. Chest 2004; 126: 773S [DOI: 10.1378/ches t.126.4_MeetingAbstracts.773S-a]
69. Dornhöfer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, Wong C, Kaper F, Sutphin P, Nacamuli R, Höckel M, Le Q, Longaker M, Yang G, Koong A, Giaccia A. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2006; 66: 5816-5827 [PMID: 16740721 DOI: 10.1158/0008-5472.CAN-06-0081]
70. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther 2006; 5: 1108-1116 [PMID: 16731742 DOI: 10.1158/1535-7163. MCT-05-0516]